• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Manfred Welslau, MD: Ongoing Research on Biosimilar Rituximab

Video

Manfred Welslau, MD, Onkologie Aschaffenburg, Germany, discusses ongoing research on biosimilar rituximab, Rixathon.

Transcript

Well it's just a safety analysis, and it’s the first interim safety analysis of about 80 patients. Another study recruited in March, so we will get the information of 182 patients, and they are now recorded but they [have not] finished their therapy. So we expect the first efficacy results this year. We're looking for efficacy, complete remission, and after the end of the therapy, and the second endpoint with [progression-free survival, PFS) rate at 12 months. So we have to wait at least 1 more year to look at this point.

Recent Videos
Sophia Humphreys, PharmD
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN
Ivo Abraham, PhD, RN.
Jeffrey Casberg, MS, RPh
Jeffrey Casberg, RPh, MS.
Related Content
© 2024 MJH Life Sciences

All rights reserved.